Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intra-Cellular Therapies (ITCI) reports stellar Q4 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q4 2022, driven by robust sales growth of CAPLYTA and a focus on expanding clinical programs.
While facing challenges in managing expenses and navigating market dynamics, the company is well-positioned to capitalize on opportunities in new indications and patient education initiatives.
ITCI's strategic investments in innovation and market expansion underscore its commitment to long-term growth and addressing mental health needs through novel treatment options.

Intra-Cellular Therapies reports robust Q1 performance and growth prospects

ITCI's strong Q1 performance driven by CAPLYTA and promising results from lumateperone studies position the company well for future growth.
Addressing unmet needs in MDD and bipolar depression, along with ongoing pipeline progress, showcases ITCI's commitment to innovation in neuropsychiatric treatments.
While facing challenges in market share data and increasing expenses, opportunities lie in expanding sales force, new indications for pipeline programs, and driving awareness for CAPLYTA.

Intra-Cellular Therapies (ITCI) reports strong Q2 performance and expands treatment portfolio

Intra-Cellular Therapies (ITCI) demonstrated robust performance in Q2, driven by strong revenue growth and promising developments in its product portfolio.
The company's financial strength, innovative pipeline, and focus on addressing unmet medical needs position it well for future growth and success.
While facing challenges in revenue guidance clarity and resource allocation, ITCI has opportunities to expand its market reach and improve patient outcomes.
By leveraging its strengths and addressing challenges effectively, Intra-Cellular Therapies (ITCI) can capitalize on opportunities to drive continued growth and innovation.

Intra-Cellular Therapies (ITCI) excels in Q3, eyes market expansion

Intra-Cellular Therapies (ITCI) showcased strong financial performance and growth prospects in Q3 2023, driven by CAPLYTA's success and pipeline advancements.
While the company faces challenges in sustaining growth and navigating regulatory complexities, opportunities in market expansion and innovation are key for future success.
ITCI's focus on expanding indications, clinical advancements, and financial strength position it well for continued growth and leadership in the pharmaceutical industry.

Intra-Cellular Therapies (ITCI) reports robust growth and strategic expansion

Intra-Cellular Therapies (ITCI) delivered a strong performance in 2023, with robust revenue growth and strategic plans for pipeline advancement and market expansion.
The company faces challenges in managing expenses, optimizing market penetration, and navigating competitive dynamics, but opportunities in sales growth and innovation are evident.
Overall, Intra-Cellular Therapies (ITCI) is well-positioned for continued success, with a focus on driving growth through product differentiation and market positioning.

Intra-Cellular Therapies (ITCI) reports strong Q1 earnings and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong Q1 2024 earnings driven by robust CAPLYTA sales and positive results in MDD studies, positioning the company for future growth.
With a solid financial position, a broad label strategy, and a focus on pipeline expansion, ITCI is well-equipped to capitalize on market opportunities and drive long-term success.
While facing near-term uncertainties and challenges, ITCI's strategic initiatives and ongoing studies present significant opportunities for expanding its market reach and revenue potential.
Overall, ITCI's commitment to developing innovative medicines and its market acceptance indicate a promising outlook for sustained growth and value creation.

Intra-Cellular Therapies (ITCI) reports robust Q3 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q3 2024, driven by CAPLYTA's sales growth and strategic investments in R&D.
The company's focus on innovation, with new program initiations and pipeline advancements, positions it well for future growth and market expansion.
While facing challenges in a competitive market and cost management, ITCI's solid financial position and promising pipeline offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

Intra-Cellular's schizophrenia drug meets main goal in late-stage trial

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

CAPLYTA Q3 2024 net product sales were   $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024.

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications & Investor Relations Sharon Mates - Founder, Chairman & Chief Executive Officer Mark Neumann - Executive Vice President & Chief Commercial Officer Lawrence Hineline - Senior Vice President of Finance & Chief Financial Officer Suresh Durgam - Executive Vice President & Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Brian Abrahams - RBC Capital Markets Dina Ramadane - Bank of America Securities Charles Duncan - Cantor Fitzgerald Marc Goodman - Leerink Partners Michael DiFiore - Evercore ISI Jeff Hung - Morgan Stanley Ami Fadia - Needham & Company Joseph Thome - TD Cowen Graig Suvannavejh - Mizuho Securities Joel Beatty - Baird David Amsellem - Piper Sandler Operator Good morning ladies and gentlemen and welcome to Intra-Cellular Therapies Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition.

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

CAPLYTA Q2 2024 net product sales were   $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, August 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2024.

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?

Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.

Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe

Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

News for Intra-Cellular Therapies Stock (ITCI)